Download our Latest Briefing →

The Future of the U.S. Oncology Market
Preparing for Healthcare 2.0

Fill in your info on the right to receive the complimentary 15-page briefing directly in your inbox →

As the costs for cancer treatments are escalating, how do you adjust to the new market realities? Will emerging payment models and risk sharing agreements define your reimbursement strategy?

eyeforpharma’s latest paper presents cross-industry analysis on reimbursement and market access strategies. Insights you don’t want to miss!



Our in-depth analysis has been written to help you:
  • Overcome barriers to traditional premium pricing
  • Re-align stakeholder partnerships in the context of evidence-based care and clinical pathways
  • Leverage risk-sharing agreements as a mechanism of market access in the US
  • Achieve favorable reimbursement through ECV differentiation and value added services
  • Prepare for demands around companion diagnostics
And of course, you’ll get an easy to read document you can share with your team and use as a basis for your next meeting.

Just fill out the form and receive the complimentary briefing directly in your inbox →


Once you had look, please let me know about your experience and where you think the analyzed trends are going.

Ulrich B. Neumann
U.S. Director
eyeforpharma

ulrich@eyeforpharma.com
201 204 1688

eyeforpharma is a trading name of FC Business Intelligence Ltd.
Registered in England and Wales no.4388971. Registered address 7-9 Fashion Street, London, E1 6PX, UK | Terms and conditions

Get the briefing now

eyeforpharma will not rent, sell, or share your personal information with any 3rd parties or non-affiliated companies